|
At Baker Tilly Virchow Krause, LLP, our experience and knowledge of the unique dynamics that drive the manufacturing industry makes us a strong partner for companies in a market sector where innovation and competition challenge them to plan and act with strategic vigor. The Baker Tilly professionals who serve this sector offer a comprehensive, proactive approach to financial, operational, and tax planning. We help manufacturing companies widen profit margins, tighten operations, and compete effectively in a fast-changing global marketplace. | Manufacturing Financial Services | Manufacturing Operational Services | - International and domestic accounting and attestation
- Acquisition support and due diligence
- Federal grant and program application assistance and compliance
- Company and divisional sell-side support
- Carve-out accounting
- Fresh start accounting
- Product costing
- International Financial Reporting Standards
| - International marketing and business development
- Management reporting systems
- National and international expansion
- Sustainable solutions
- Alternative energy feasibility
- Strategic sourcing
- Supply chain and operations improvement
- Worldwide project management
- Technology and enterprise
| | Manufacturing Tax Services | | - Advanced energy manufacturing tax credit
- Compliance reporting
- FAS 109 and FIN 48 compliance
- International credits and incentives
- Inventory shrinkage/obsolescence
- Exemption tax analysis
- US domestic research tax credits
- Sale and use tax consulting
- Uniform capitalization rules
- Cost segregation studies
- Tax accounting methods
| |
| Recent Insights for Manufacturers | The Qualifying Therapeutic Discovery Project Credit: How to Best Position Your Company
On March 23, 2010, the President signed the Patient Protection and Affordable Care Act, Pub. L. No. 111-148 (the “Act”). The Act created Internal Revenue Code section 48D, Qualifying Therapeutic Discovery Project Credit, which provides a tax credit equal to 50 percent of the “qualified investment” of an “eligible taxpayer” for certain research and development expenditures in 2009 and/or 2010 related to certain qualified projects. For companies that cannot currently utilize this as a tax credit, a cash grant of the same amount is available. The total amount of credits/grants that may be allocated under the program will not exceed $1 billion. While many details are still emerging, this article provides an abridged overview of the credit, what to expect from the Federal government in the coming month, and most importantly, how to best position your company to be selected for this competitive program.
Read More >
Therapeutic Discovery Project Credit Webinar - May 26, 2010 - 12:00 pm CDT
With a firm $1 billion in funds being made available, the application process is going to be highly competitive. Biotech and life sciences companies looking to receive the credit need to start gathering and preparing their responses now. Join Baker Tilly as we discuss the Qualifying Therapeutic Discovery Project Credit - a credit designed to encourage medical science investments for 2009 and 2010.
More information on this event >
Register Today >
| | |
|
.png)
